Workshop II: "neuroprotection"--the Lugano consensus.
Consensus could be reached that there is overwhelming evidence of preclinical neuroprotection. However, the evidence of neuroprotection/neurorescue under clinical conditions is limited. Lessons from clinical trials designed to show neuroprotection (selegiline, amantadine, dopamine agonists) demonstrate that with the drugs available neuroprotection/neurorescue has to start as early as possible. A PET-controlled clinical trial with ropinirole shows that there seems to be a good chance for neuroprotection in the early phase of Parkinson's disease in patients treated from the very beginning of the disease while there is no such benefit in patients with a late start of a neuroprotective therapeutic strategy. Also long-term neuroprotection cannot be reached. Complicating factors to demonstrate clinical neuroprotection are discussed.
Riederer
P
P
Clinical Neurochemistry, Clinic and Policlinic of Psychiatry and Psychotherapy, University of Würzburg, Germany.
Brücke
T
T
Buhmann
C
C
Müller
T
T
Schwartz
A
A
Storch
A
A
Winner
B
B
D002986:Clinical Trials as Topic / Q000706:statistics & numerical data; D015259:Dopamine Agents / Q000494:pharmacology* / Q000627:therapeutic use; D004358:Drug Therapy / Q000592:standards; D004493:Education; D006801:Humans; D009410:Nerve Degeneration / Q000188:drug therapy* / Q000517:prevention & control*; D018696:Neuroprotective Agents / Q000494:pharmacology*; D010300:Parkinson Disease / Q000188:drug therapy* / Q000503:physiopathology; D013557:Switzerland
D015259:Dopamine Agents; D018696:Neuroprotective Agents